Investigational drug · Phase 2
AZD9550
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Overweight and Obesity, Obesity/Overweight, Obesity or Overweight.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
7
Any phase or sponsor naming "AZD9550"
First trial start
2023
Sep 29, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD9550", any sponsor or status.
Conditions studied
As listed on its trial records.
- Overweight and Obesity
- Obesity/Overweight
- Obesity or Overweight
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD9550" as an intervention, largest first.
- A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs AlonePivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT06862791 · 377 participants · Start Feb 18, 2025 · Primary completion May 11, 2026
Drug: AZD9550; AZD6234 and 1 more · For: Obesity or Overweight
Sites: Dothan, Alabama; Vestavia Hills, Alabama; Cerritos, California · 53 sites in all
- A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and OverweightPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06151964 · 166 participants · Start Sep 29, 2023 · Primary completion Jan 29, 2027
Drug: AZD9550; placebo and 1 more · For: Overweight and Obesity
Sites: Graz, Austria; Vienna, Austria; Surrey, Canada · 15 sites in all
AstraZenecaAstraZeneca (AZN)
NCT07013643 · 100 participants · Start Jun 4, 2025 · Primary completion Jul 9, 2027
Drug: AZD6234; Ethinyl estradiol/Levonorgestrel (EE/LEVO) and 2 more · For: Healthy Participants
Sites: Glendale, California; Brooklyn, Maryland
- A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234Not yet recruiting
AstraZenecaAstraZeneca (AZN)
NCT07911514 · 60 participants (planned) · Start Nov 9, 2026 · Primary completion May 4, 2027
Drug: AZD9550 solution for injection; AZD6234 solution for injection and 4 more · For: Healthy Participants
Sites: Ruddington, United Kingdom
AstraZenecaAstraZeneca (AZN)
NCT05848440 · 48 participants · Start May 2, 2023 · Primary completion Nov 13, 2023
Drug: AZD9550; AZD9550 and 1 more · For: Non-alcoholic Steatohepatitis
Sites: Harrow, United Kingdom
AstraZenecaAstraZeneca (AZN)
NCT07546760 · 28 participants (planned) · Start Mar 20, 2026 · Primary completion Feb 4, 2027
Drug: AZD6234; AZD9550 · For: Hepatic Impairment
Sites: Chandler, Arizona; Rialto, California; Miami Lakes, Florida · 4 sites in all
- This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / OverweightActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT07017179 · 16 participants · Start May 20, 2025 · Primary completion Oct 23, 2026
Drug: AZD6234; Placebo and 4 more · For: Obesity/Overweight
Sites: Jinan, China; Nanjing, China; Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Overweight and Obesity
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- LenbelintideAZD6234Phase 39 trials
AstraZeneca · Obesity or Overweight, Obesity, Overweight
- MazdutideLY3305677Phase 35 trials
Eli Lilly · Type 2 Diabetes, Obesity, Overweight
- HDM1002Phase 34 trials
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight and Obesity
- DA-302168SPhase 33 trials
Chendu DIAO Pharmaceutical Group CO., LTD. · Overweight and Obesity, Type 2 Diabetes Mellitus
- TE-8105 MADPhase 22 trials
Immunwork, Inc. · Overweight and Obesity
- CPX101Phase 21 trial
Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd. · Overweight and Obesity
- WVE-007Phase 21 trial
Wave Life Sciences USA, Inc. · Overweight and Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.